Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Investigation of Pembrolizumab (Keytruda) in Combination With Radiation and an Immune Modulatory Cocktail in Patients With Cervical and Uterine Cancer (PRIMMO Trial)

NCT03192059 is registered in ClinicalTrials.gov with University Hospital, Ghent as lead sponsor.

NCT NCT03192059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03192059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Investigation of Pembrolizumab (Keytruda) in Combination With Radiation and an Immune Modulatory Cocktail in Patients With Cervical and Uterine Cancer (PRIMMO Trial)
Lead sponsor
University Hospital, Ghent
Phase
Phase 2
Overall status
Completed
Start date
July 1, 2017
Completion date
June 30, 2021
Enrollment
43 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, endometrial cancer, uterine cancer